白介素抑制剂市场- 按类型（IL-1、IL-2、IL-5、IL-6、IL-17 和IL-23 抑制剂）、给药途径（皮下、静脉注射）、应用（类风湿关节炎、牛皮癣、 IBD、气喘），最终用户 - 全球预测 2024 - 2032

受生物技术进步和自体免疫疾病盛行率上升的推动，2024年至2032年全球白血球介素抑制剂市场复合年增长率将超过12%。根据全球自体免疫研究所的数据，自体免疫疾病影响工业化国家 5% 至 10% 的人口。儘管研究表明，发展中国家自体免疫疾病的盛行率较低，但正在逐渐增加，其中类风湿性关节炎和牛皮癣是最常见的。

不断的研发努力导致了新的、更有效的白细胞介素抑制剂的推出，增强了针对健康状况的治疗选择。此外，对自体免疫疾病的认识不断提高和早期诊断正在推动对标靶治疗的更高需求，与传统治疗相比，标靶治疗更有效且副作用更少。

整个白细胞介素抑制剂市场根据类型、给药途径、应用、最终用户和地区进行分类。

由于 IL-17 在治疗银屑病和僵直性脊椎炎发炎性疾病方面具有针对性功效，因此到 2032 年，IL-17 领域将录得良好的复合年增长率。这些抑制剂透过特异性阻断 IL-17 细胞因子而取得了显着的临床成功，IL-17 细胞因子在这些疾病的发病机制中发挥着至关重要的作用。与更广泛的免疫抑制疗法相比，这种有针对性的方法可以更有效地减轻症状并最大限度地减少副作用，从而改善患者的治疗效果。患者越来越偏好副作用较少的治疗方法，这有利于 IL-17 抑制剂的采用。

由于治疗药物的快速有效输送，静脉 (IV) 领域预计到 2032 年将占据显着的行业份额。静脉注射可确保血液中快速达到高药物浓度，这对于控制急性发炎和优化治疗结果至关重要。此外，静脉注射途径通常可以控制和精确剂量，从而提高治疗效果和患者依从性。对快速有效的治疗反应的需求正在增加静脉注射的使用。

北美白细胞介素抑制剂产业在 2024 年至 2032 年间将实现显着的复合年增长率。自体免疫疾病的盛行率不断上升，加上寻求有效和有针对性的治疗的患者人数不断增加，刺激了需求。此外，北美领先製药公司的存在以及新药快速的监管审批流程进一步加速了市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球自体免疫疾病盛行率不断上升
    • 老年人口不断增加
    • 提高消费者意识
    • 生物疗法的技术进步
  • 产业陷阱与挑战
    • 治疗费用高
    • 副作用和不良反应
• 成长潜力分析
• 管道分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• IL-1抑制剂
• IL-2抑制剂
• IL-5抑制剂
• IL-6抑制剂
• IL-17抑制剂
• IL-23抑制剂
• 其他类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 皮下注射（SC）
• 静脉注射 (IV)

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 类风湿关节炎
• 牛皮癣
• 发炎性肠道疾病（IBD）
• 气喘
• 其他应用

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 研究和学术机构

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Abbvie Inc.
• Biogen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• Genentech USA, Inc.
• Janssen Pharmaceutical Companies (Johnson and Johnson)
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Samsungbioepis Co,.Ltd.
• Sanofi
• Sobi, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• UCB S.A

Global Interleukin Inhibitors Market will experience over 12% CAGR from 2024 to 2032, bolstered by advancements in biotechnology and the increasing prevalence of autoimmune diseases. According to the Global Autoimmune Institute, autoimmune diseases impact between 5 to 10% of the population in industrialized countries. Although research indicates that the prevalence of autoimmune diseases is lower in developing nations, it is gradually increasing, with rheumatoid arthritis and psoriasis being among the most common.

Constant R&D efforts are leading to the introduction of new and more effective interleukin inhibitors, enhancing treatment options for health conditions. Additionally, the rising awareness and early diagnosis of autoimmune disorders are contributing to higher demand for targeted therapies, which are more efficient and have fewer side effects compared to traditional treatments.

The overall interleukin inhibitors market is sorted based on type, route of administration, application, end-user, and region.

The IL-17 segment will record a decent CAGR through 2032, due to their targeted efficacy in treating inflammatory conditions such as psoriasis and ankylosing spondylitis. These inhibitors have demonstrated significant clinical success by specifically blocking the IL-17 cytokine, which plays a crucial role in the pathogenesis of these diseases. This targeted approach improves patient outcomes by reducing symptoms more effectively and minimizes side effects compared to broader immunosuppressive therapies. The growing patient preference for therapies with fewer side effects is favoring the adoption of IL-17 inhibitors.

The intravenous (IV) segment is slated to record a notable industry share by 2032, due to rapid and effective delivery of therapeutics. IV administration ensures that high drug concentrations are achieved quickly in the bloodstream, which is crucial for managing acute inflammatory conditions and optimizing therapeutic outcomes. Additionally, the IV route often allows for controlled and precise dosing, enhancing treatment efficacy and patient adherence. The need for swift and potent therapeutic responses is augmenting the uptake of IV delivery.

North America interleukin inhibitors industry will record a remarkable CAGR between 2024 and 2032. The region's advanced healthcare infrastructure and significant investment in biotechnology research facilitate the development and adoption of innovative solutions. The increasing prevalence of autoimmune diseases, coupled with a rising patient population seeking effective and targeted therapies, fuels demand. Furthermore, the presence of leading pharmaceutical companies and the rapid regulatory approval process for new drugs in North America is further accelerating the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of autoimmune disease globally
    • 3.2.1.2 Growing elderly population
    • 3.2.1.3 Increasing consumer awareness
    • 3.2.1.4 Technological advancements in biologic therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of the treatment
    • 3.2.2.2 Side effects and adverse reactions
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 IL-1 inhibitors
• 5.3 IL-2 inhibitors
• 5.4 IL-5 inhibitors
• 5.5 IL-6 inhibitors
• 5.6 IL-17 inhibitors
• 5.7 IL-23 inhibitors
• 5.8 Other types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Subcutaneous (SC)
• 6.3 Intravenous (IV)

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Rheumatoid arthritis
• 7.3 Psoriasis
• 7.4 Inflammatory bowel disease (IBD)
• 7.5 Asthma
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital
• 8.3 Specialty clinics
• 8.4 Research and academic institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbvie Inc.
• 10.2 Biogen Inc.
• 10.3 Eli Lilly and Company
• 10.4 F. Hoffmann-La Roche Ltd.
• 10.5 Fujifilm Kyowa Kirin Biologics Co., Ltd.
• 10.6 Genentech USA, Inc.
• 10.7 Janssen Pharmaceutical Companies (Johnson and Johnson)
• 10.8 Novartis AG
• 10.9 Regeneron Pharmaceuticals, Inc.
• 10.10 Samsungbioepis Co,.Ltd.
• 10.11 Sanofi
• 10.12 Sobi, Inc.
• 10.13 Sun Pharmaceutical Industries Ltd.
• 10.14 Teva Pharmaceuticals Industries Ltd.
• 10.15 UCB S.A